Merck’s Oral PCSK9 Inhibitor and Nurix’s BTK Degrader Among ACS First Disclosures

The First Disclosures section of the 2023 ACS Spring Meeting in Indianapolis, organized by GSK’s Nikki Goodwin, covers three novel small molecules and an ADC this year.

The molecules include:

  • MK-0616, Merck’s macrocyclic oral PCSK9 inhibitor (presented by Abbas Walji)
  • NX-2127, Nurix’s oral BTK degrader (presented by Jeff Wu)
  • BI 1015550, Boehringer Ingelheim’s PDE4 inhibitor for IPF (presented by Horst Dollinger)
  • ABBV-154, an ADC with a glucocorticoid receptor modulator payload (presented by Adrian Hobson)
MK-0616 Merck PCSK9 chemical structure, NX-2127 Nurix Therapeutics BTK degrader structure, BI 1015550 PDE4B inhibitor for IPF, ABBV-154 structure

More notes on each of the molecules and why they matter appear below. This page will continue to be updated after the conference.

MK-0616, Merck’s macrocyclic oral PCSK9 inhibitor

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

This field is for validation purposes and should be left unchanged.

Join Subscribers from

…and hundreds more!